idorsia ebook advert

Lucerastat, a new oral therapy for Fabry patients in development

Idorsia Pharmaceuticals, a Swiss biotech company, is developing lucerastat, a new oral therapy for patients with Fabry Disease. The Phase 3 clinical study MODIFY has just enrolled its first patients and will investigate the use of lucerastat monotherapy for the treatment of adult patients with Fabry disease, irrespective of their genetic mutation type. The MODIFY … Continue reading “Lucerastat, a new oral therapy for Fabry patients in development”

Read More

Subscribe to Our Newsletter